NAS10029,465−1.17%S&P7,723−0.27%GOLD$4,035−0.40%BTC$81,733+0.57%VIX16.46−2.66%latest tape · as of 16:04 UTC
The Screen · Healthcare · Biotechnology
OLMAOlema Pharmaceuticals, Inc.
OLMA · Nasdaq · USD · Market cap $841M · 137 employees
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers.
FAIL · Does not pass the screen
6.41 USD
Price as of 23 Oct 2026Daily close, not a live quoteLast reviewed 6 days ago
Screened 2026-10-23 · the tape above runs as of 16:04 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
Price6.41 USD at the 23 Oct 2026 close
Ethical screenDoes not pass
OptionsOpen interest leans to puts (put/call 2.38)
Last reviewed23 Oct 2026 (6 days ago)
A summary of the dated readings below, not a live quote and not advice.
PRICE · FAIR-VALUE RANGE1M3M6MYTD1Y3Y5Y
What this means: price 6.41 against the desk's fair-value range, over the last year.
Positioning no disclosures inside 60 days, left as found
Options put/call open interest 2.38, read 2026-10-28
Ethical does not pass the values gate
Price6.41 USD
Ethical score70.0/100
Our investment reviews on this name
2026-07-02Read Markdown9.87-35.1% to today ✓First review on file: Markdown
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Olema Pharmaceuticals, Inc. holds its Markdown at $6.41. Elevated stress, defensive posture warranted, held for 105 days.
As held on the ledger · 2026-10-23
Phase
Markdown · caution
Quantitative state
Elevated stress, defensive posture warranted, held for 105 days
Price at the screen
$6.41
Valuation
N/A trailing · -3.98 forward price to earnings
Values screen
FAIL· score 70.0
Beta
2.00
The Workings
Five Screens, Shown in Full
Does not pass. Interest-bearing securities
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
0.79%
Below 33%
Interest-bearing debt is just 0.8% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
85.70%
Below 33%
Interest-bearing cash and securities are 85.7% of assets, above the one-third limit.
Fail
Receivables
9.82%
Below 49%
Money owed to the company is 9.8% of assets, under the 49% limit.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Olema Pharmaceuticals,'s business is fine, but its cash and interest-bearing securities are about 86% of its assets, well over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-10-28. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when OLMA's ethical verdict changes
Today OLMA does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
Third-party analyst targets: 10 covering, consensus Strong Buy. The average target sits +524% from the screen price.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-23 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; it already moves more than the market on an average day; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
OLMA trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-28Markdown$6.80+0.0%Entry 9
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading oversold. Over the past year the shares are up 134%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (11 analysts) rates it strong buy, with a mean price target of $42.
2026-10-21Markdown$6.80-13.0%Entry 8
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 13.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading oversold. Over the past year the shares are up 134%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (11 analysts) rates it strong buy, with a mean price target of $42.
2026-10-14Markdown$7.82-18.8%Entry 7
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 18.8% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading oversold. Over the past year the shares are up 134%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (11 analysts) rates it strong buy, with a mean price target of $42.
2026-10-02Markdown$9.63-2.4%Entry 6
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 2.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading oversold. Over the past year the shares are up 134%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (11 analysts) rates it strong buy, with a mean price target of $42.
2026-09-08Markdown$9.87+0.0%Entry 5
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading oversold. Over the past year the shares are up 134%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (11 analysts) rates it strong buy, with a mean price target of $42.
2026-08-07Markdown$9.87+0.0%Entry 4
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading oversold. Over the past year the shares are up 134%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (11 analysts) rates it strong buy, with a mean price target of $42.
2026-07-18Markdown$9.87+0.0%Entry 3
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading oversold. Over the past year the shares are up 134%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (11 analysts) rates it strong buy, with a mean price target of $42.
2026-07-03Markdown$9.87+0.0%Entry 2
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns.
2026-07-02Markdown$9.87Entry 1
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
What Holding Actually Paid · Price Plus Dividends
If $1,000 had been placed · historical, not a promise
Period
Price then
Price return
Divs per share
$1,000 became
Total return
1 month
$14.86
-33.6%
·
$664
-33.6%
2 months
$16.10
-38.7%
·
$613
-38.7%
3 months
$14.91
-33.8%
·
$662
-33.8%
6 months
$31.58
-68.8%
·
$313
-68.8%
1 year
$4.21
+134.4%
·
$2,344
+134.4%
2 years
$13.56
-27.2%
·
$728
-27.2%
3 years
$7.82
+26.2%
·
$1,262
+26.2%
5 years
$28.81
-65.7%
·
$343
-65.7%
Historical returns from market close data. Past performance does not guarantee future results.
The Ledger's Promise
This entry now belongs to the ledger. Whatever OLMA does next, these words stay.
Olema Pharmaceuticals, Inc. · OLMA · Markdown · $6.41
Recorded 2026-10-23 · before the outcome · scored mechanically